Nova Chemicals operates in both the basic and specialty chemicals segments. The IPD division that produced basic chemicals is under review for sale to United Chemicals due to its apparent poor performance. On further review it appears that the offer of $160 million is much lower than the actual value once the R&D expense is reallocated. At the same time since the IPD division does not share synergies with the other divisions it is recommended to either spin off the division or institute a tracking stock to make its actual value transparent to the market and thereby prepare it for a future sale. In order to raise the capital for a capacity expansion for the high growth Environmental Products division we recommend a mix of debt and equity since a pure debt financing will violate the interest coverage ratio covenant. Nova is not managing IPD efficiently, but United's offer is inadequate. Due to the low growth in the basic chemicals segment relative to specialty chemicals, internal investments prior to 1988 were not used to upgrade IPD facilities. IPD therefore had a cost disadvantage over its competitors due to its inflexible plants. As a diversified chemicals company, Nova was underperforming. Compared with the other diversified chemicals companies, Nova had the lowest P/E ratio (10.3) and the lowest Value/Sales ratio (0.76). Since IPD is not integrated with the rest of company, it is relatively easy to conduct a valuation of IPD. Given that IPD does not receive any benefit from Nova's R&D efforts a more representative valuation for IPD can be obtained by adjusting the EBIT upward in our calculations to compensate for the over-allocated R&D . Here are some valuation figures for IPD to compare against United Chemicals offer of $160 million which after considering the tax benefits is worth $236 million (160 + 0.4*190) to Nova Chemicals:
Based on DCF without R&D expense adjustment -
Based on DCF with R&D expense...
Please join StudyMode to read the full document